奈必洛尔对冠心病合并慢性阻塞性肺疾病患者的疗效
[Efficacy of nebivolol in patients with coronary heart disease and concomitant chronic obstructive pulmonary disease].
作者信息
Kotliarov A A, Mosina L M, Chibisov S M, Selezneva N M, Shmyreva M V, Efremova E N, Surotkina S A
出版信息
Klin Med (Mosk). 2011;89(1):44-8.
The study was designed to assess clinical efficiency and safety of nebivolol in patients with cardiovascular problems and chronic obstructive pulmonary disease. It included 50 patients of whom 25 were given daily 5 and 25 mg of nebivolol and 80-100 mg of verapamil. Nebivolol was shown to significantly reduce arterial pressure, heart rate, and the number of ventricular extrasystoles. The drug was well tolerated by the patients and had no adverse effect on bronchial patiency.
该研究旨在评估奈必洛尔对有心血管问题和慢性阻塞性肺疾病患者的临床疗效和安全性。研究纳入了50名患者，其中25名患者每日服用5毫克和25毫克奈必洛尔以及80 - 100毫克维拉帕米。结果显示，奈必洛尔能显著降低动脉血压、心率和室性早搏的次数。患者对该药物耐受性良好，且对支气管通畅性无不良影响。
Zotero 插件